Verifi® by Retrogen: Non-Invasive Prenatal Testing
The Verifi® Prenatal Test represents a major advance in prenatal testing, providing accurate answers about fetal chromosomal health without the risk associated with invasive procedures, such as amniocentesis or chorionic villus sampling (CVS).
The Verifi® Prenatal Test is a non-invasive prenatal screening that checks for multiple fetal chromosomal aneuploidies using a single maternal blood draw with high sensitivity and specificity. Verifi® by Retrogen accurately detects aneuploidies such as trisomy 21 (associated with Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome).
Verifi® prenatal testing is:
- Safe – Routine, non-invasive blood draw. Just one tube (7-10 mL).
- Accurate – Directly analyzes cell-free fetal and maternal DNA with our proprietary SAFeRTM algorithm, which has a very low failure rate (0.1%).
- Easy – Test as early as 10 weeks gestational age (8 weeks of fetal age as determined by date of conception). No limitations regarding ethnicity, BMI, assisted reproductive technology (ART), or egg donor cases.
- Fast – Results reported to partner laboratory in 3-5 business days after sample receipt (time to report may vary based on partner laboratory providing the test).
In comparison to other screening options, non-invasive prenatal testing provides more reliable results with a higher positive predictive value than traditional serum screens. Additionally, it does not carry the risk of complications that invasive procedures can have.
Non-Invasive Prenatal Testing.
Chromosomes 21, 18, and 13.
Detection of aneuploidies.
#1001 Verifi® Non-Invasive Prenatal Test.
4-6 business days after sample receipt.
7-10 mL of venous blood.
- ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007:109:217-227.
- American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545: noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol. 2012:120:1532-1534.
- Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med. 2013:15:395-398
- Benn P, Borell A, Chiu R, et al. Position Statement from the Aneuploidy Screening Committee on Behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn. 2013;33:622-629.
- Devers PL, Cronister A, Ormond KE, Facio F, Brasington CK, Flodman P. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. J Genet Couns. 2013:22:291-295.
- Bhatt S, Parsa S, Snyder H, Taneja P, Halks-Miller M, Seltzer W, DeFeo E. Clinical Laboratory Experience with Noninvasive Prenatal Testing: Update on Clinically Relevant Metrics. ISPD 2014 poster.
- Verinata Health, Inc. (2012) Analytical Validation of the XXX Prenatal Test: Enhanced Test Performance For Detecting Trisomies 21, 18 and 13 and the Option for Classification of Sex Chromosome Status. Redwood City, CA.
- Futch T, Spinosa J, Bhatt S, de Feo E, Rava RP, Sehnert AJ. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. Prenat Diagn. 2013:33:569-574.
- Data on file: Internal data from lab metric updates.
- Norton ME, Brar H, Weiss J, et al. Noninvasive chromosomal evaluation (NICE) study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012;207:137.e1-8.
- Pergament E, Cuckle H, Zimmermann B, et al. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol. 2014;124:210-218.